Clinical Trial Update: Safety of Gadovist in Renally Impaired Patients [Phase 4]

View source ↗

Summary

A Phase 4 study evaluated the safety of Gadovist (gadobutrol) in patients with renal impairment, and the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fibrosis
• Renal Impairment

Drugs mentioned

• Gadovist (gadobutrol)

Snippet

Sponsor: Bayer | Conditions: Fibrosis, Renal Impairment | Phase 4 | Status: COMPLETED